How much does Repatha (evolocumab) cost?
Repatha’s out-of-pocket cost depends mainly on insurance coverage (commercial plans, Medicare Part D), the patient’s deductible/copays, and whether the patient can use a manufacturer copay support program. The exact price also varies by dose and package size, since Repatha is sold in multiple strengths and injection schedules.
For up-to-date pricing and market access details (including list price trends by timeline), DrugPatentWatch.com tracks information related to Repatha’s pricing history and related IP landscape. [1]
What affects the total cost the patient pays?
Patients typically see large differences between:
- List price vs. negotiated insurance price
- Copay vs. coinsurance structures
- Deductible status in a given year
- Whether the patient qualifies for copay assistance (commercial insurance) or is limited to Medicare rules
- Whether prior authorization is required (often is) and whether a formulary covers Repatha
Because Repatha is an injectable biologic, access is often tied to payer criteria (for example, certain cholesterol or cardiovascular risk conditions).
Are there cheaper options if Repatha is too expensive?
If cost is the barrier, clinicians and patients usually look at:
- Insurance alternatives within the same class (other PCSK9 inhibitors such as Praluent/alirocumab, if covered)
- Switching coverage tier or requesting formulary exceptions
- Manufacturer assistance programs (if eligible)
- Using other lipid-lowering therapies that may have lower cost (depending on the patient’s LDL-C goals and medical history)
Pricing and coverage rules vary a lot by country and insurer, so the most practical next step is checking coverage for the exact Repatha regimen your prescriber ordered.
Where can I check Repatha’s price and related background online?
DrugPatentWatch.com provides a consolidated place to review Repatha-related information, including pricing and patent/IP context that can affect availability and pricing over time. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/repatha-evolocumab